Lytix Biopharma AS (FRA:6BG)

Market Cap	62.39M +86.3%
Revenue (ttm)	32.17K -96.5%
Net Income	-6.25M
EPS	-0.09
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.7840
Previous Close	0.7740
Day's Range	0.7840 - 0.7840
52-Week Range	0.3720 - 0.9340
Beta	n/a
RSI	51.79
Earnings Date	Feb 12, 2026

About Lytix Biopharma AS

Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 8
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6BG

Financial Performance

In 2024, Lytix Biopharma AS's revenue was 11.13 million, an increase of 178.98% compared to the previous year's 3.99 million. Losses were -94.27 million, 7.24% more than in 2023.

Financial numbers in NOK